NCT04042376View on ClinicalTrials.gov

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

PHASE4CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 18, 2019

Primary Completion Date

March 19, 2024

Study Completion Date

March 19, 2024

Conditions
Waldenstrom Macroglobulinemia
Interventions
DRUG

Ibrutinib

Ibrutinib will be administered orally, once daily, at a dose of 420 mg (140 mg\*3 capsules taken together at one time).

Trial Locations (6)

130021

The First Hospital of Jilin University, Changchun

300320

Institute of Hematology and Blood Diseases Hospital, Tianjin

310003

First affiliated Hospital of Zhejiang University, Hangzhou

430023

Wuhan Union Hospital, Wuhan

450008

Henan Cancer Hospital, Zhengzhou

710004

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04042376 - A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) | Biotech Hunter | Biotech Hunter